All thanks to the group of drugs termed Glucagon-like Peptide-1 (GLP1) agonists (like Ozempic, Wegovy), which lower blood sugar levels, promote weight loss by enhancing insulin secretion, reduce appetite, and slow digestion
Patients with certain genetic profiles may benefit more from semaglutide alone, while others respond better to dual-agent therapy like GLP-Squared (semaglutide plus tirzepatide combined)
However, the median duration of adverse symptoms when starting the new medication was only 8 days, 3 days, and 2 days for nausea, diarrhea, and vomiting, respectively
Bone and Mineral Support Bone and mineral support remains important, particularly when intake is reduced for extended periods